Synonym
Arbekacin sulfate
IUPAC/Chemical Name
(S)-4-amino-N-((1R,2S,3S,4R,5S)-5-amino-2-(((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4-(((2R,3R,6S)-3-amino-6-(aminomethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-hydroxycyclohexyl)-2-hydroxybutanamide sulfate
InChi Key
UTUVRPOLEMRKQC-XDJMXTNXSA-N
InChi Code
1S/C22H44N6O10.H2O4S/c23-4-3-12(30)20(34)28-11-5-10(26)18(37-21-9(25)2-1-8(6-24)35-21)17(33)19(11)38-22-16(32)14(27)15(31)13(7-29)36-22;1-5(2,3)4/h8-19,21-22,29-33H,1-7,23-27H2,(H,28,34);(H2,1,2,3,4)/t8-,9+,10-,11+,12-,13+,14-,15+,16+,17-,18+,19-,21+,22+;/m0./s1
SMILES Code
O1[C@H](O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]2[C@H](N)CC[C@H](CN)O2)N)NC([C@H](CCN)O)=O)[C@H](O)[C@@H](N)[C@@H](O)[C@H]1CO.S(O)(O)(=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
650.70
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Lee JH, Lee CS. Clinical Usefulness of Arbekacin. Infect Chemother. 2016 Mar;48(1):1-11. doi: 10.3947/ic.2016.48.1.1. Epub 2016 Mar 31. Review. PubMed PMID: 27104010; PubMed Central PMCID: PMC4835429.
2: Matsumoto T, Hanaki H, Kimura T, Nemoto M, Higashihara M, Yokota H, Oda S, Akiyama N, Miyao N, Yoshida M, Yukioka T, Soma K, Ohyashiki K, Suzuki Y, Arai T, Ikegami K, Ichiwata T, Otsuka Y, Kobayashi M, Totsuka K, Sunakawa K; ABK Dose Finding Study Group. Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study. J Infect Chemother. 2013 Feb;19(1):128-37. doi: 10.1007/s10156-012-0519-z. Epub 2012 Dec 22. PubMed PMID: 23263188.
3: Yamamoto Y, Izumikawa K, Hashiguchi K, Fukuda Y, Kobayashi T, Kondo A, Inoue Y, Morinaga Y, Nakamura S, Imamura Y, Miyazaki T, Kakeya H, Yanagihara K, Kohno S. The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection. J Infect Chemother. 2012 Apr;18(2):241-6. doi: 10.1007/s10156-012-0397-4. Epub 2012 Mar 8. PubMed PMID: 22398881.
